Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

lefradafiban

Known as: 5-((((4'-(imino(methoxycarbonyl)amino)methyl)(1,1'-biphenyl)-4-yl)oxy)methyl)-2-oxo-pyrrolidineacetic acid, methyl ester 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Biphenyl CompoundsPyrrolidines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Platelet Glycoprotein IIb / IIIa Receptor Inhibitors – Role in Coronary Artery Disease
Gp IIb/IIIa receptor antagonists are potent antiplatelet agents since they block the final pathway in platelet aggregation… 
  • table III
  • table II
  • table IV
2001
2001
Orbofiban: An orally active GPIIb/IIIa platelet receptor antagonist
A key role has been established for platelet activation and thrombus formation in the pathogenesis of acute coronary syndromes… 
2001
2001
Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty
OBJECTIVE Lefradafiban is the orally active prodrug of fradafiban, a glycoprotein IIb/IIIa receptor antagonist. The present phase… 
2000
2000
Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study.
AIMS Oral glycoprotein IIb/IIIa inhibitors might enhance the early benefit of an intravenous agent and prevent subsequent cardiac… 
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
2000
2000
Absorption of lefradafiban from different sites of the gastrointestinal tract.
AIMS Fibrinogen receptor antagonists show a close relationship between plasma concentrations and inhibitory effect. Optimal… 
1999
1999
A whole blood assay of inhibition of platelet aggregation by glycoprotein IIb/IIIa antagonists: comparison with other aggregation methodologies.
We have used a whole blood single-platelet counting assay (WB-SPC) that is sensitive to microaggregation for monitoring GPIIb… 
1999
1999
Lefradafiban. BIBU 104, BIBU 104XX.
  • Drugs in R&D
  • 1999
  • Corpus ID: 12469367
Review
1998
Review
1998
Glycoprotein IIb/IIIa receptor antagonists in the management of cardiovascular diseases.
  • P. Chong
  • American journal of health-system pharmacy : AJHP…
  • 1998
  • Corpus ID: 3113775
Recent studies of the effects of glycoprotein (GP) IIb/IIIa receptor antagonists on the clinical outcomes of patients with… 
Review
1998
Review
1998
Platelet inhibition: new agents, new strategies, new trials
Summary Since platelet aggregation is dependent on the presence of functional GP IIb/IIIa receptors and since this receptor is… 
Highly Cited
1997
Highly Cited
1997
Profound and sustained inhibition of platelet aggregation by Fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, Lefradafiban, in men.
BACKGROUND Clinical trials have demonstrated that platelet glycoprotein (GP) IIb/IIIa antagonists effectively prevent acute… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE